{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:10:38Z","timestamp":1784585438675,"version":"3.55.0"},"reference-count":34,"publisher":"Consilium Medicum","issue":"7","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim.To assess the safety and efficacy of autologous haematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients with dialysis-dependent renal failure.\r\nMaterials and methods.During a period from May 2010 to December 2016 fourteen MM patients with dialysis-dependent renal failure aged 48 to 65 years underwent auto-HSCT. After the induction therapy complete response, very good partial response, partial response were documented in 64, 29, 7% of patients, respectively. In no case was a renal response achieved. Haematopoietic stem cell mobilization in most patients (13\/14) was performed according to the scheme: G-CSF 10 g\/kg. Melphalan in 3 dosages was used as pre-transplant conditioning: 100, 140 and 200 mg\/m2; 13 patients underwent a single and in one case underwent a tandem auto-HSCT against the background of hemodialysis. Evaluation of the antitumor and renal response was assessed on the 100th day after auto-HSCT. Subsequently, against the background of programmed hemodialysis and in the setting of high-dosed melphalan (100200 mg\/m2), 13 patients underwent a single and one patient underwent a tandem auto-HSCT. At +100 days after auto-HSCT, an antitumor response and renal response were assessed.\r\nResults.The period of agranulocytosis after auto-HSCT was from 5 to 12 days (median 8,5) and was accompanied by infectious complications, cardiac and neurological dysfunctions. At +100 days after auto-HSCT, the complete response was confirmed in 71% patients and very good partial response was confirmed in 29% patients. The minimal renal response was registered in 2 patients (14%), hemodialysis was stopped. The transplant-related mortality was absent. After a median follow-up of 53 months 5-year progression-free survival was 59%, and overall survival was 93%.\r\nConclusion.Carrying out auto-HSCT in patients with dialysis-dependent renal failure contributed to the achievement of a minimal renal response in 14% of cases, which allowed these patients to stop hemodialysis. Patients whose conditioning regimen was performed using melphalan at a dose of 200 mg\/m2showed more frequent complications in the early post-transplant period compared to patients who received a lower dose of melphalan (100140 mg\/m2). Auto-HSCT in MM patients with dialysis-dependent renal failure is a feasible and effective treatment method, which in some cases contributes to independence from hemodialysis.<\/jats:p>","DOI":"10.26442\/00403660.2020.07.000777","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T05:42:50Z","timestamp":1599889370000},"page":"70-76","source":"Crossref","is-referenced-by-count":5,"title":["Autologous haematopoietic stem cell transplantation in patients with multiple myeloma complicated by dialysis-dependent renal failure"],"prefix":"10.26442","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-171X","authenticated-orcid":false,"given":"M. V.","family":"Firsova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4966-8146","authenticated-orcid":false,"given":"L. P.","family":"Mendeleeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-6202","authenticated-orcid":false,"given":"M. V.","family":"Solovev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5440-4340","authenticated-orcid":false,"given":"I. G.","family":"Rekhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8657-4990","authenticated-orcid":false,"given":"O. S.","family":"Pokrovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-6532","authenticated-orcid":false,"given":"E. S.","family":"Urnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-2446","authenticated-orcid":false,"given":"N. P.","family":"Soboleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-0796","authenticated-orcid":false,"given":"V. N.","family":"Dvirnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-5763","authenticated-orcid":false,"given":"G. A.","family":"Klyasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-6276","authenticated-orcid":false,"given":"L. A.","family":"Kuzmina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-5557","authenticated-orcid":false,"given":"V. G.","family":"Savchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0044"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90221.x"},{"key":"ref3","unstructured":"Mendeleeva LP, Solovev MV, Alexeeva A, et al. Multiple Myeloma in Russia (First Results of the Registration Trial). Blood. 2017;130(S1):5408."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705860"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.377"},{"key":"ref6","unstructured":"Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-138. doi: org\/10.1038\/kisup.2012.1"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-445304"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw056"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2013.08.009"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/167125"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.12.028"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04590908"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"\u0411\u0438\u0440\u044e\u043a\u043e\u0432\u0430 \u041b.\u0421., \u0420\u0435\u0445\u0442\u0438\u043d\u0430 \u0418.\u0413., \u041c\u0435\u043d\u0434\u0435\u043b\u0435\u0435\u0432\u0430 \u041b.\u041f. \u0414\u0438\u0430\u043b\u0438\u0437\u0437\u0430\u0432\u0438\u0441\u0438\u043c\u0430\u044f \u043f\u043e\u0447\u0435\u0447\u043d\u0430\u044f \u043d\u0435\u0434\u043e\u0441\u0442\u0430\u0442\u043e\u0447\u043d\u043e\u0441\u0442\u044c \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u043e\u0439: \u0444\u0430\u043a\u0442\u043e\u0440\u044b \u043e\u0431\u0440\u0430\u0442\u0438\u043c\u043e\u0441\u0442\u0438. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2015;87(7):72-6 [Biryukova LS, Rekhtina IG, Mendeleeva LP. Dialysis-dependent Renal Failure in Patients With Multiple Myeloma: Reversibility Factors. Therapeutic Archive. 2015;87(7):72-6 (In Russ.)]. doi: 10.17116\/ terarkh201587772-76","DOI":"10.17116\/terarkh201587772-76"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801930506"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv283"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt483"},{"key":"ref18","unstructured":"Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2(6):947-52."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06191.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704440"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00446.x"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03033.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8791"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91(10):3662-70.","DOI":"10.1182\/blood.V91.10.3662"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401819"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.03.021"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Waszczuk-Gajda A, Lewandowski Z, Drozd-Soko\u0142owska J, et al. Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients-DAUTOS Study of the Polish Myeloma Study Group. Eur J Haematol. 2018;101(4):475-85. doi: org\/10.1111\/ejh.13101","DOI":"10.1111\/ejh.13101"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0122-8"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.226"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0697-8"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2509"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13994"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/43126\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/43126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:39:41Z","timestamp":1634157581000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/43126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2020.07.000777","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}